Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Equities researchers at Dawson James issued their Q4 2019 earnings per share (EPS) estimates for shares of Spring Bank Pharmaceuticals in a research report issued on Monday, May 13th. Dawson James analyst R. Wasserman expects that the company will post earnings of ($0.54) per share for the quarter.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald set a $29.00 target price on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, April 12th. Chardan Capital set a $25.00 target price on Spring Bank Pharmaceuticals and gave the company a “buy” rating in a report on Friday, April 12th. Zacks Investment Research lowered Spring Bank Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. Finally, ValuEngine lowered Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Spring Bank Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $23.80.

SBPH stock opened at $7.08 on Wednesday. The stock has a market cap of $116.42 million, a price-to-earnings ratio of -3.79 and a beta of 0.53. Spring Bank Pharmaceuticals has a twelve month low of $6.30 and a twelve month high of $15.00.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its earnings results on Monday, April 29th. The company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.20.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its position in Spring Bank Pharmaceuticals by 1.4% in the 1st quarter. BlackRock Inc. now owns 684,927 shares of the company’s stock worth $7,184,000 after purchasing an additional 9,594 shares during the last quarter. Vanguard Group Inc raised its position in shares of Spring Bank Pharmaceuticals by 34.8% in the 3rd quarter. Vanguard Group Inc now owns 549,186 shares of the company’s stock worth $6,618,000 after acquiring an additional 141,730 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Spring Bank Pharmaceuticals by 34.8% in the 3rd quarter. Vanguard Group Inc. now owns 549,186 shares of the company’s stock worth $6,618,000 after acquiring an additional 141,730 shares in the last quarter. Northern Trust Corp raised its position in shares of Spring Bank Pharmaceuticals by 7.2% in the 1st quarter. Northern Trust Corp now owns 184,064 shares of the company’s stock worth $1,931,000 after acquiring an additional 12,314 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Spring Bank Pharmaceuticals by 8.7% in the 4th quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock worth $1,214,000 after acquiring an additional 9,398 shares in the last quarter. 43.08% of the stock is owned by institutional investors.

In related news, insider Martin J. Driscoll bought 10,000 shares of Spring Bank Pharmaceuticals stock in a transaction on Tuesday, April 30th. The stock was acquired at an average price of $7.34 per share, with a total value of $73,400.00. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.60% of the stock is owned by insiders.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Featured Article: How do buyers and sellers choose a strike price?

Earnings History and Estimates for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.